Navigation Links
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
Date:6/1/2009

tiple myeloma: Preliminary results" (Abstract #8541).

About Multiple Myeloma

According to the American Cancer Society, in 2009, approximately 20,500 new cases of multiple myeloma will be diagnosed in the United States. Newly diagnosed patients have treatment options that include combination chemotherapeutic agents and stem cell transplantation. While many patients respond to treatment, most eventually relapse and require subsequent treatment. Few patients are ultimately cured of their disease. In spite of advances in the treatment of multiple myeloma, this year alone, approximately 10,500 patients are expected to die of the disease.

About Carfilzomib

Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's macroglobulinemia, mantle cell lymphoma and renal cell carcinoma.

Proteolix is conducting a comprehensive clinical development program evaluating carfilzomib for the treatment of multiple myeloma, including an ongoing accelerated approval study in heavily pre-treated relapsed/refractory patients and a Phase 2 clinical trial in relapsed patients stratified by prior treatment with bortezomib. Both Phase 2 clinical trials are being conducted by Proteolix in collaboration with the Multiple Myeloma Research Consortium (MMRC). A Phase 1b clinical trial of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma is also ongoing. In addition, Proteolix is conducting a single-agent Phase 2 clinical trial of carfilzomib in patients with recurrent or advanced solid tumors. For the la
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
2. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
4. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
5. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
11. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...  Air Products (NYSE: APD ) understands ... vital to any healthcare facility. This understanding has driven ... the efficiency of its oxygen supply systems, but also ... systems for emergency oxygen supply and high ... the 51 st ASHE Annual Conference & ...
(Date:7/28/2014)... Research and Markets  has announced the addition ... report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... to inflammation and pain in the human body,s joints such ... causes inflammation of the tissues that surround the joints and ... RA begin slowly, usually just mild pain around the joints ...
(Date:7/28/2014)... July 28, 2014  TNI BioTech, Inc. (OTCQB: ... focused on the development, marketing and distribution of ... definitive proxy materials with the Securities and Exchange ... of Shareholders to be held on Thursday, September ... The record date for determining those shareholders eligible ...
Breaking Medicine Technology:Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Global Rheumatoid Arthritis Drugs Market 2014-2018 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3
... Institute and Gallo Research Center today announced ... (SoRI-9409) will be published in the December ... publication is available online,today at the journal,s ... that,causes selective and long-lasting reduction in ethanol ...
... ALTO, Calif., Sept. 11 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... participation in the first Phase III pivotal clinical trial,of ... The JZP-6 Phase III clinical trial program includes two ... patients at 65 centers in the U.S. The second ...
Cached Medicine Technology:Novel Compound Shows Promise for Treatment of Alcoholism 2Novel Compound Shows Promise for Treatment of Alcoholism 3Novel Compound Shows Promise for Treatment of Alcoholism 4Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia 2Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia 3
(Date:7/28/2014)... Co (PRWEB) July 28, 2014 Drorit ... has unveiled new plans to raise investment capital through ... 24/7 fitness concept in the United States. , According ... popularity of 24/7 fitness centers provide a great window ... this rapidly expanding space. In addition to this, Silverman ...
(Date:7/28/2014)... 2014 "Fist bumping" transmits significantly fewer bacteria ... the cultural expectation of hand-to-hand contact between patients ... the August issue of the American Journal ... the Association for Professionals in Infection Control and ... Institute of Biological, Environmental, and Rural Sciences at ...
(Date:7/28/2014)... 2014 The Wireline Services Market in Europe ... with analysis and forecast of revenue. The Wireline services market ... in 2013 to $2.4 billion by 2019, at a CAGR ... TOC of the Wireline Services Market in Europe report, to ... provides a glimpse of the segmentation in the European Wireline ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... to have a slightly increased risk of potentially fatal ... researchers report. Doctors have previously suspected that babies ... risk of deep vein thrombosis and pulmonary embolism, two ... the researchers noted in background information. This new ...
(Date:7/28/2014)... The Oneida Indian Nation today announced ... of accompanying PGA TOUR players will be teeing up ... Begay III for the seventh annual Notah Begay III ... Casino ’s Atunyote® Golf Club on Wednesday, August 27, ... Dufner, Jimmy Walker, Jonas Blixt, Angel Cabrera and Louis ...
Breaking Medicine News(10 mins):Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Fist-bumping beats germ-spreading handshake, study reports 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 3Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 2Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 3Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 4Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 5
... , ... embrace new technology. , ... MA (PRWEB) January 11, 2010 -- SonRidge, LLC, a catering and chef supplies company located ... for their clients in the food industry. What they discovered was an innovative resolution that ...
... ... and marketer of all-natural sunscreen products launched their website at solaraegis.com. , ... (PRWEB) January 13, 2010 -- ... products launched their website at www.solaraegis.com ., , , , ,"The site ...
... ... and financial security pet health insurance makes sense. Veterinarians once skeptical to the value ... insurance. , ... PA (PRWEB) January 14, 2010 -- Pet Health Insurance in the United States and ...
... ... stresses importance of greater awareness of brain injuries and serious lifelong implications for victims ... San Francisco, ... Year,s Day, in which top-ranked American snowboarder Kevin Pearce suffered a severe brain injury ...
... led by Professor Eduardo Franco, Director of McGill University,s ... colleagues from McGill and Universit de Montral/Centre Hospitalier de ... per cent) of young adults in a new sexual ... nearly half (44 per cent) were infected with an ...
... , , , NEW YORK ... a leading provider of software to public retirement organizations, announced ... System implementation for the State Teachers Retirements System of ... as a replacement to their legacy contributions, pension, disbursement, and ...
Cached Medicine News:Health News:Insulated Transport Containers Go Green 2Health News:SolarAegis, LLC. Website Helps You Have Fun In the Sun, Safely 2Health News:Pet Health Insurance Grows as Pets Live Longer and Healthier Lives 2Health News:Pet Health Insurance Grows as Pets Live Longer and Healthier Lives 3Health News:Pet Health Insurance Grows as Pets Live Longer and Healthier Lives 4Health News:Pet Health Insurance Grows as Pets Live Longer and Healthier Lives 5Health News:Snowboarding Accident Provides Tragic Reminder of Serious Risk of Brain Injuries in Athletic and Occupational Environments 2Health News:McGill-CHUM study: 56 percent of young adults in a new sexual relationship infected with HPV 2Health News:State Teachers Retirement System of Ohio Goes Live on V3 Benefits Administration System 2Health News:State Teachers Retirement System of Ohio Goes Live on V3 Benefits Administration System 3
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 23G x 5/8in (.60 x 16mm)...
... for LASIK surgery and other types of ... interface and/or stromal bed. Flattened tip provides ... elevate the flap edge. Multiple ports provide ... 22mm) Formed 9mm from end. Two .15mm ...
... for LASIK surgery and other types ... the corneal interface and/or stromal bed. ... the flap and helps elevate the ... irrigation. 21G x 7/8in (.80 x ...
Medicine Products: